Abstract
Interference of the binding of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) has become a new inspiring immunotherapy for resisting cancers. To date, the FDA has approved two PD-1 monoclonal antibody drugs against cancer as well as a monoclonal antibody for PD-L1. More PD-1 and PD-L1 monoclonal antibody drugs are on their way in clinical trials. In this review, we focused on the mechanism of the PD-1/PD-L1 signaling pathway and the monoclonal antibodies (mAbs) against PD-1 and PD-L1, which were approved by the FDA or are still in clinical trials. And also presented is the prospect of the PD-1/PD-L1 immune checkpoint blockade in the next generation of immunotherapy.
Original language | English |
---|---|
Article number | 1151 |
Number of pages | 22 |
Journal | International Journal of Molecular Sciences |
Volume | 17 |
Issue number | 7 |
DOIs | |
Publication status | Published - 18 Jul 2016 |
Scopus Subject Areas
- Catalysis
- Molecular Biology
- Spectroscopy
- Computer Science Applications
- Physical and Theoretical Chemistry
- Organic Chemistry
- Inorganic Chemistry
User-Defined Keywords
- Immunotherapy
- Monoclonal antibodies (mAbs)
- PD-1 (Programmed cell death protein 1)
- PD-L1 (Programmed death-ligand 1)